Danrong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danrong Lin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ganying Chen
Department of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China
1 shared publication - Jinxian Chen
Department of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China
1 shared publication - Junbin Liao
School of Public Health, Southern Medical University, Guangzhou 510515, China
1 shared publication - Qingqing Feng
Department of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China
1 shared publication - Ruiting Wang
Department of Scientific Research Management, Guangzhou Center for Disease Control and Prevention (Guangzhou Health Supervision Institute), Guangzhou 510440, China
1 shared publication - Wei Zhu
Guangzhou Center for Disease Control and Prevention, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 27 February 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (3) , 157
Development of an Anti-Zearalenone Nanobody Phage Display Library and Preparation of Specific Nanobodies
Zearalenone (ZEN), a toxic estrogenic mycotoxin in cereals, threatens human and animal health through reproductive, immune, and cytotoxic effects, necessitating sensitive detection methods. While nanobodies offer advantages over conventional antibodies for on-site ZEN detection, their application remains unexplored. This study aimed to develop an anti-ZEN nanobody derived from an anti-ZEN phage display nanobody library. An alpaca was immunized with a ZEN-bovine serum albumin (ZEN-BSA) antigen, achieving peak serum antibody titers (1:25,600) following four immunizations. A high-capacity phage display nanobody library (1.0 × 1011 plaque-forming units/mL) was constructed. Following four rounds of biopanning, an enrichment factor of 479 was achieved. Phage ELISA screening identified six phage display nanobodies with specific ZEN-binding activity, and multiple sequence alignment revealed four unique nanobody sequences. The selected phage display nanobody, designated phage-V44, was expressed and purified, and its presence was validated by SDS-PAGE and western blotting, which detected a single approximately 17 kDa band consistent with the expected nanobody size. We established a working curve for an indirect competitive enzyme-linked immunoassay (ELISA) for ZEN, which showed an IC50 value of 7.55 ng/mL. The specificity and affinity of the V44 were also verified. Collectively, the study successfully constructed an anti-ZEN phage display nanobody library, screened four specific ZEN-binding phage display nanobodies, and prepared the anti-ZEN nanobody V44. Thereby establishing a foundation for the nanobody’s future integration into rapid on-site detection methods for ZEN in both animal feed and human food products.
- 27 February 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (3) , 157
Open AccessDevelopment of an Anti-Zearalenone Nanobody Phage Display Library and Preparation of Specific Nanobodies
Zearalenone (ZEN), a toxic estrogenic mycotoxin in cereals, threatens human and animal health through reproductive, immune, and cytotoxic effects, necessitating sensitive detection methods. While nanobodies offer advantages over conventional antibodies for on-site ZEN detection, their application remains unexplored. This study aimed to develop an anti-ZEN nanobody derived from an anti-ZEN phage display nanobody library. An alpaca was immunized with a ZEN-bovine serum albumin (ZEN-BSA) antigen, achieving peak serum antibody titers (1:25,600) following four immunizations. A high-capacity phage display nanobody library (1.0 × 1011 plaque-forming units/mL) was constructed. Following four rounds of biopanning, an enrichment factor of 479 was achieved. Phage ELISA screening identified six phage display nanobodies with specific ZEN-binding activity, and multiple sequence alignment revealed four unique nanobody sequences. The selected phage display nanobody, designated phage-V44, was expressed and purified, and its presence was validated by SDS-PAGE and western blotting, which detected a single approximately 17 kDa band consistent with the expected nanobody size. We established a working curve for an indirect competitive enzyme-linked immunoassay (ELISA) for ZEN, which showed an IC50 value of 7.55 ng/mL. The specificity and affinity of the V44 were also verified. Collectively, the study successfully constructed an anti-ZEN phage display nanobody library, screened four specific ZEN-binding phage display nanobodies, and prepared the anti-ZEN nanobody V44. Thereby establishing a foundation for the nanobody’s future integration into rapid on-site detection methods for ZEN in both animal feed and human food products.